SCHEMBL5832045

SCHEMBL5832045

O=S(=O)(Nc1nc(-c2cccnc2)ns1)c1c(Cl)cc(Cl)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 4/20 0.46
SLC40A1 Q9NP59 1/20 0.46
KMT2A Q03164 7/20 0.43
MEN1 O00255 6/20 0.43
MAPT P10636 1/20 0.43
CYP1A2 P05177 2/20 0.41
CYP1A1 P04798 1/20 0.41
CYP1B1 Q16678 1/20 0.41
ALDH1A1 P00352 4/20 0.41
ACLY P53396 1/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2C19 P33261 2/20 0.40
LMNA P02545 1/20 0.40
CYP2C9 P11712 1/20 0.40
PKM P14618 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
RAB9A P51151 3/20 0.40
NPC1 O15118 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5831931 0.92 PFKFB3 (0.46) CYP19A1SLC40A1KMT2AMEN1MAPT
SCHEMBL5831683 0.87 ADORA3 (0.52) SLC40A1KMT2AMEN1LMNARAB9A
SCHEMBL6930430 0.86 MAPT (0.41) KMT2AMEN1MAPTALDH1A1RAB9A
SCHEMBL2762432 0.82 MEN1 (0.58) KMT2AMEN1MAPTCYP1A2CYP1A1
SCHEMBL5831082 0.80 MEN1 (0.51) SLC40A1KMT2AMEN1MAPTCYP1A2
SCHEMBL5831306 0.79 PFKFB3 (0.50) KMT2AMEN1MAPTLMNARAB9A
SCHEMBL5832082 0.79 USP36 (0.55) CYP19A1KMT2AMEN1MAPTALDH1A1
SCHEMBL5831167 0.78 KDM1A (0.47) SLC40A1KMT2AMEN1MAPTCYP1A2
SCHEMBL2762380 0.76 MEN1 (0.58) KMT2AMEN1MAPTCYP1A2CYP1A1
SCHEMBL6690050 0.75 SLC40A1 (0.49) SLC40A1KMT2AMEN1MAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004113310-A1 USE OF AN INHIBITOR OF 11-B-HYDROXYSTEROID DEHYDROGENASE TYPE 1 COMPOUNDS FOR PROMOTING WOUND HEALING BIOVITRUM AB (SE) 2004-12-29 WO claimed
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
US-7074788-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-07-11 US disclosed
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics CPT1A, HSD11B1, CES1 CYP19A1 173/4885SLC40A1 1213/4885KMT2A 2980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.